| Strain Name |
C57BL/6-Pdcd1tm1(PDCD1)Bcgen Cd40tm1(CD40)Bcgen/Bcgen
|
Common Name | B-hPD-1/hCD40 mice |
| Background | C57BL/6 | Catalog number | 120526 |
|
Related Genes |
PD-1 (Programmed death-1) ； CD40 (CD40 antigen) |
||
|
NCBI Gene ID |
18566,21939 | ||
Protein expression analysis
Strain specific CD40 and PD-1 expression analysis in homozygous B-hPD-1/hCD40 mice by flow cytometry. Splenocytes were collected from WT and homozygous B-hPD-1/hCD40 (H/H) mice analyzed by flow cytometry with species-specific anti-PD-1 antibody and anti-CD40 antibody. Mouse CD40 and PD-1 were detected in WT. Human CD40 and PD-1 were exclusively detected in H/H B-hPD-1/hCD40 but not WT mice.
Combination therapy of PD-1 mAb (keytruda) and CD40 mAb
Antitumor activity of anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda in B-hPD-1/hCD40 mice. (A) Anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibodies keytruda inhibited MC38-hPD-L1 tumor growth in B-hPD-1/hCD40 mice. Murine colon cancer MC38-hPD-L1 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hCD40 mice (female, 6 week-old, n=8). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hCD40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hCD40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hCD40 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.
Combination therapy of PD-1 mAb (keytruda) and CD40 mAb
Antitumor activity of anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda in B-hPD-1/hCD40 mice. (A) Anti-hCD40 antibody Selicrelumab (in house) combined with anti-hPD-1 antibodies keytruda inhibited MC38 tumor growth in B-hPD-1/hCD40 mice. Murine colon cancer MC38 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hCD40 mice (female, 4 week-old, n=8). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with antibody Selicrelumab (in house) combined with anti-hPD-1 antibody keytruda with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hCD40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hCD40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hCD40 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.
Combination therapy of PD-1 mAb (keytruda) and CD40 mAb
